Despite so many articles rehabilitating soy far too many people still believe it is harmful. The obvious truth appears to escape them: why would a crop enjoyed for millennia without any problems become a problem in the last few decades? The answer is simple: genetic manipulation and its manipulation to produce artificial fats.

Otherwise soy is a healthy crop consumed widely in Asia without any hormonal problems. Yes, it has PHYTOESTROGENS, just like linseed (flax), sesame seeds, wheat, berries, oats, barley, dried beans, lentils, yams, rice, alfalfa, mung beans, apples, carrots, pomegranates, wheat germ, rice bran, soy linseed bread, ginseng, etc. Are you going to stop consuming them, too?

The scientists who coined the term Phytoestrogens regrets it to this day. It created a storm of misunderstandings that has problem difficult to overcome in certain consumer circles. Soy has been blamed for menstrual irregularities and breast cancer. Interestingly, xenoestrogens in the environment, that is, toxins that have an estrogen effect in the body are seldom trotted out as more likely causes. This is the proverbial choking on gnats and swallowing camels.

Soy will not harm you, even when you already have breast cancer. If a person has a negative reaction to soy is because of allergies or sensitivities that have their genesis in the liver and the microbiome. People with poor bacterial balance in the gut develop allergies and many other issues that may cause any food, to be digested less optimally. In fact, the salutary effects of soy are due to its conversion to EQUOL in the gut.

If you eat soy that has been fermented and untouched by Monsanto (GMO) you are likely to do just fine.


“The Effects of Soy Isoflavones on Metabolic Status of Patients With Polycystic Ovary Syndrome,” JCEM 2016;101(9), pp. 3386–3394.

Soy isoflavone administration for 12 weeks in women with PCOS significantly improved markers of insulin resistance, hormonal status, triglycerides, and biomarkers of oxidative stress. Soy isoflavones administration for 12 weeks in PCOS women significantly improved markers of insulin resistance, hormonal status, triglycerides and biomarkers of oxidative stress.

“The Inhibition of Estrogenic Effects of Pesticides and Environmental Chemicals by Curcumin and isoflavonoids (soy),” J. Environmental Health Perspectives 1998;106:807

“Dietary intake and breast cancer among carriers and noncarriers of BRCA mutations in the Korean Hereditary Breast Cancer Study,”  Am J Clin Nutr 2013 98: 1493

J.Menopause 2000;7:214. “Why would one view phytoestrogens (soy) as an alternative. Given what we know about the synergistic effects of multiple agents, I wonder how the combined use of phytoestrogens and hormones would affect postmenopausal women. Clinical science will likely move away from looking at single agents…[and study the] effects of combinations of agents and behaviors, looking to maximize synergism. This is the complimentary school of thought. Although such an approach requires more resources, complementary medicine is theoretically more powerful and more realistic because it more closely models behavioral reality.


 It is intrinsically appealing because it captures some of what we already intuit, which is that the whole is greater than the sum of the parts… Integrative Medicine is a critical undertaking that has enormous public health implications. We are moving beyond single agent paradigms. We are recognizing that health comes not from a single factor but from synergism of factors. Foods contain known and unknown nutrients. By extracting the presumed active ingredients, we may leave behind valuable constituents in the matrix. We are being forced to account for complexity.”

For more information, visit


Bridge of Light Productions
 A Division of New Galaxy Enterprises
Phone: 760-323-0193 email:


Bridge of Light Productions, a Division of New Galaxy Enterprises, Inc., a California Corporation, is proud to offer the world the perfect Christmas gift, a song we believe rivals White Christmas, Winter Wonderland, It’s Beginning to Look a Lot Like Christmas, Chestnuts Roasting on an Open Fire and other classics. By visiting, Christmas enthusiasts, whether buyers, gift givers or potential affiliates, can preview Christmas In Your Eyes and hear the lustrous sounds of the remarkable Patricia Welch.

Patricia Welch has spent much of her career in musical theatre, playing Tuptim with Yul Brynner in the Broadway Production of The King and I. She worked right alongside Robert Goulet in his show, The Man And His Music, singing duets with him and as a featured soloist in his tour throughout the United States, performing with him for a 2007 PBS Special. In 2005-2006 Patricia was also featured soloist in the Wayne Newton Show. She has recently released a 46-song album, Cocktails With Patricia, Great Songs From the 50’s, 60’s, 70’s, 80’s & 90’s. (

Christmas In Your Eyes was produced by Bridge of Light Productions, a joint venture of Russian- American songwriting team, Edgar Arens, a composer and resident of Moscow in the Russian Federation, and Johnny Blue Star, lyricist and CEO of New Galaxy Enterprises, Inc., a California Corporation. Edgar Arens, (, an emerging film composer and musician who just scored the Russian TV mini-series, The Secret Agent’s Memoir. Edgar single-handedly, created the richly, textured orchestral vehicle for Christmas In Your Eyes, a song which, again, we believe could only be considered a modern Christmas classic.

“We are pleased to offer our song not only to consumers for themselves or to give Christmas gifts, but also to potential affiliates who can share in our revenue stream by signing up for free at our website,” says Johnny Blue Star (, President of New Galaxy Enterprises, a company devoted to development of book and film franchises as well as music, through its Bridge of Light Production Division. “. Great Christmas songs have always been a powerful legacy of each Christmas season and it is great to offer folks the perfect Christmas present for only $1.00 by just purchasing a coupon on our website.”

Patricia Welch says, “I have been fortunate in being able to work with various stars and sing some of the greatest songs ever written as part of my repertoire. But now that I’ve started to work with Johnny and Edgar, I am looking forward to a really creative and original collaboration. As a performer, I think there’s nothing more exciting than to work with original, cutting edge material, no matter what the genre.”

Mike Merrick, the famed Broadway producers of shows like “Passion,” “Copperfield,” “Clarence Darrow” and “The Belle of Amherst,” has this to say about the song: “Christmas in Your Eyes” is an inspirational song, performed by an inspirational singer, Patricia Welch. Her interpretation of the beauty of the song, affords it with the true meaning it is meant to convey. A perfect blending of artist and musical materia.”

To preview the Christmas In Your Eyes, go to For record labels interested in this song or other original songs by Arens and Blue Star, as performed by Patricia Welch, please contact Johnny Blue Star, Manager of Bridge of Light at 760-323-0193 or email him at




BAD GENES? DON’T ROLL OVER—TAKE CHARGE! An Integrative View of Genetics.

Weekly, I am asked by fear-driven patients about genetic testing, and if there is something they can do to avert their dim genetic future. These poor patients have been led to believe that their genes are cast in stone and that the same diseases their parents suffered with are most certainly looming in a future awaiting them with doom and gloom.

Shame on those responsible for this pessimistic view of Nature. Why have these purveyors of genetic damnation not informed patients about EPIGENETICS? This new science is not getting much attention despite solid evidence backing its principal tenant, that our genes are influenced by our ENVIRONMENT, not only the food we eat, but the chemicals/toxins we are surrounded by, and even by our relationships and thoughts.

Please, google Epigenetics. You must not take my word for this. You will find that it literally means “Above Genetics.” Ask yourself who stands to gain by genetic fear mongering; not you, that is for sure.

EPIGENETICS arguably began with a study of ~45,000 separated twins in Scandinavia. They developed diseases (or not) independent of the other twin, thus proving that their environment and diets determined their health more than genes (NEJM JULY 13TH 2000;343:78.) For instance, one twin with diabetic parents was similarly affected due to his poor lifestyle and diabetogenic toxins, while his twin did not become diabetic by avoiding those negative factors.

Again, don’t take my word for it. Study the evidence yourself:

Combating Environmental Causes of Cancer  NEJM 2011;364:7991

Gene-environment interplay  J. Science 2007 Oct 2016 : 15

Warburg meets epigenetics  J. Science 28 Oct 2016 : 419-420  (Glycolysis promotes T cell function by an epigenetic mechanism. Warburg won the Nobel Prize in Medicine in 1931 for saying that excessive sugar in our diet increases the risk of cancer.)

October 28 2016 issue


 January 18 2010 issue




A monthly review of 50 medical journals
Volume 17 Number 12 December 2016

From time to time a single medical article encapsulates the simple concepts to which I have dedicated three decades of professional work. At first I got nothing but grief trying to pass on to others what I found in smaller journals. But, now that the best of journals (J. Nature Medicine, J. Science, J. Cell, J. Gastroenterology, J. Scientific American, J. Nature, etc.,) have highlighted these concepts on their covers it is time for all doctors to apply them. Below you will find the summary of the latest thunderbolt on how important nutrition and your gut flora are. At least ponder the extraordinary implications of the abstract below. The 149 references are for those who wish to study the issue for themselves.

Pass on this issue to your other doctors.

Hugo Rodier, MD

Signals from the gut microbiota to distant organs in physiology and disease, J. Nature Medicine November 2016; 22:1079–1089

“The ecosystem of the human gut consists of trillions of bacteria forming a bioreactor that is fueled by dietary macronutrients to produce bioactive compounds. These microbiota-derived metabolites signal to distant organs in the body, which enables the gut bacteria to connect to the immune and hormone system, to the brain (the gut–brain axis) and to host metabolism, as well as other functions of the host. This microbe–host communication is essential to maintain vital functions of the healthy host. Recently, however, the gut microbiota has been associated with a number of diseases, ranging from obesity and inflammatory diseases to behavioral and physiological abnormalities associated with neurodevelopmental disorders. In this Review, we will discuss microbiota–host cross-talk and intestinal microbiome signaling to extraintestinal organs. We will review mechanisms of how this communication might contribute to host physiology and discuss how misconfigured signaling might contribute to different diseases.”

1. Sender, R., Fuchs, S. & Milo, R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164, 337–340 (2016).
2. Zoetendal, E.G., Akkermans, A.D. & De Vos, W.M. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl. Environ. Microbiol. 64, 3854–3859 (1998).
3. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
4. Eckburg, P.B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005).
5. Hold, G.L., Pryde, S.E., Russell, V.J., Furrie, E. & Flint, H.J. Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol. Ecol. 39, 33–39 (2002).
6. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
7. Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834–841 (2014).
8. Tamburini, S., Shen, N., Wu, H.C. & Clemente, J.C. The microbiome in early life: implications for health outcomes. Nat. Med. 22, 713–722 (2016).
9. Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174–180 (2011).
10. Knights, D. et al. Rethinking “enterotypes”. Cell Host Microbe. 16, 433–437 (2014).
11. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222–227 (2012).
12. Kovatcheva-Datchary, P. et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab. 22, 971–982 (2015).
13. Kommineni, S. et al. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature 526, 719–722 (2015).
14. Pédron, T. et al. A crypt-specific core microbiota resides in the mouse colon. MBio 3, e00116–e00112 (2012).
15. Kaiko, G.E. et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell 165, 1708–1720 (2016).
16. Haag, L.-M. & Siegmund, B. Intestinal microbiota and the innate immune system—a crosstalk in Crohn’s disease pathogenesis. Front. Immunol. 6, 489 (2015).
17. Honda, K. & Littman, D.R. The microbiota in adaptive immune homeostasis and disease. Nature 535, 75–84 (2016).
18. Thaiss, C.A., Zmora, N., Levy, M. & Elinav, E. The microbiome and innate immunity. Nature 535, 65–74 (2016).
19. Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 449, 819–826 (2007).
20. Cani, P.D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007).
21. Hersoug, L.-G., Møller, P. & Loft, S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes. Rev. 17, 297–312 (2016).
22. Ghoshal, S., Witta, J., Zhong, J., de Villiers, W. & Eckhardt, E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J. Lipid Res. 50, 90–97 (2009).
23. Bäckhed, F., Normark, S., Schweda, E.K.H., Oscarson, S. & Richter-Dahlfors, A. Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes Infect. 5, 1057–1063 (2003).
24. Vatanen, T. et al. Variation in microbiome LPS mmunogenicity Contributes to Autoimmunity in Humans. Cell 165, 842–853 (2016).
25. Larsson, E. et al. Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut. 61, 1124–1131 (2012).
26. Gaboriau-Routhiau, V. et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31, 677–689 (2009).
27. Chung, H. et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149, 1578–1593 (2012).
28. Kashyap, P.C. et al. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology 144, 967–977 (2013).
29. Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372–385 (2013).
30. Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22, 598–605 (2016).
31. Bergman, E.N. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol. Rev. 70, 567–590 (1990).
32. Bäckhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101, 15718–15723 (2004).
33. Bäckhed, F., Manchester, J.K., Semenkovich, C.F. & Gordon, J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl. Acad. Sci. USA 104, 979–984 (2007).
34. Samuel, B.S. et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl. Acad. Sci. USA 105, 16767–16772 (2008).
35. Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364–371 (2012).
36. Fava, S. Glucagon-like peptide 1 and the cardiovascular system. Curr. Diabetes Rev. 10, 302–310 (2014).
37. Nøhr, M.K. et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 154, 3552–3564 (2013).
38. De Vadder, F. et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156, 84–96 (2014).
39. Frost, G. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014).
40. Perry, R.J. et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016).
41. Kimura, I. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 4, 1829 (2013).
42. Midtvedt, T. Microbial bile acid transformation. Am. J. Clin. Nutr. 27, 1341–1347 (1974).
43. Swann, J.R. et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl. Acad. Sci. USA 108 (Suppl. 1), 4523–4530 (2011).
44. Sayin, S.I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225–235 (2013).
45. Islam, K.B.M.S. et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141, 1773–1781 (2011).
46. Kurdi, P., Kawanishi, K., Mizutani, K. & Yokota, A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J. Bacteriol. 188, 1979–1986 (2006).
47. Li, F. et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 4, 2384 (2013).
48. Jiang, C. et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).
49. Parséus, A. et al. Microbiota-induced obesity requires farnesoid X receptor. Gut. (2016).
50. Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167–177 (2009).
51. Broeders, E.P.M. et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue Activity. Cell Metab. 22, 418–426 (2015).
52. Ryan, K.K. et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509, 183–188 (2014).
53. Tremaroli, V. et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 22, 228–238 (2015).
54. Schauer, P.R. et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N. Engl. J. Med. 370, 2002–2013 (2014).
55. McGavigan, A.K. et al. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut. (2015).
56. Fang, S. et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159–165 (2015).
57. Downes, M. et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11, 1079–1092 (2003).
58. Neuschwander-Tetri, B.A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).
59. Cypess, A.M. et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509–1517 (2009).
60. Wang, Q.A., Tao, C., Gupta, R.K. & Scherer, P.E. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat. Med. 19, 1338–1344 (2013).
61. Harms, M. & Seale, P. Brown and beige fat: development, function and therapeutic potential. Nat. Med. 19, 1252–1263 (2013).
62. Ziętak, M. et al. Altered microbiota contributes to reduced diet-induced obesity upon cold exposure. Cell Metab. 23, 1216–1223 (2016).
63. Chevalier, C. et al. Gut microbiota orchestrates energy homeostasis during Cold. Cell 163, 1360–1374 (2015).
64. Suárez-Zamorano, N. et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat. Med. 21, 1497–1501 (2015).
65. Collins, S. & Surwit, R.S. The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog. Horm. Res. 56, 309–328 (2001).
66. Sommer, F. et al. The gut microbiota modulates energy metabolism in the hibernating brown bear Ursus arctos. Cell Rep. 14, 1655–1661 (2016).
67. Turnbaugh, P.J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).
68. Turnbaugh, P.J., Bäckhed, F., Fulton, L. & Gordon, J.I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 3, 213–223 (2008).
69. Turnbaugh, P.J. et al. The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 1, 6ra14 (2009).
70. Blanton, L.V. et al. Gut bacteria that prevent growth impairments transmitted by microbiota from malnourished children. Science 351, aad3311 (2016).
71. Smith, M.I. et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 339, 548–554 (2013).
72. Engfer, M.B., Stahl, B., Finke, B., Sawatzki, G. & Daniel, H. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am. J. Clin. Nutr. 71, 1589–1596 (2000).
73. Charbonneau, M.R. et al. Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition. Cell 164, 859–871 (2016).
74. Subramanian, S. et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature 510, 417–421 (2014).
75. Schwarzer, M. et al. Lactobacillus plantarum strain maintains growth of infant mice during chronic undernutrition. Science 351, 854–857 (2016).
76. Fleissner, C.K. et al. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br. J. Nutr. 104, 919–929 (2010).
77. Ding, S. et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 5, e12191 (2010).
78. Sonnenburg, E.D. et al. Diet-induced extinctions in the gut microbiota compound over generations. Nature 529, 212–215 (2016).
79. Tremaroli, V. & Bäckhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 489, 242–249 (2012).
80. Caesar, R. et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut 61, 1701–1707 (2012).
81. Caesar, R., Tremaroli, V., Kovatcheva-Datchary, P., Cani, P.D. & Bäckhed, F. Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab. 22, 658–668 (2015).
82. Luche, E. et al. Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. Mol. Metab. 2, 281–291 (2013).
83. Erridge, C., Attina, T., Spickett, C.M. & Webb, D.J. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am. J. Clin. Nutr. 86, 1286–1292 (2007).
84. Amar, J. et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol. Med. 3, 559–572 (2011).
85. Beyaz, S. et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature 531, 53–58 (2016).
86. Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 110, 9066–9071 (2013).
87. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–185 (2012).
88. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745–757 (2011).
89. Bajaj, J.S. et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G168–G175 (2012).
90. Makiura, N. et al. Relationship of Porphyromonas gingivalis with glycemic level in patients with type 2 diabetes following periodontal treatment. Oral Microbiol. Immunol. 23, 348–351 (2008).
91. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
92. Koeth, R.A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013).
93. Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111–124 (2016).
94. Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595 (2015).
95. Jonsson, A.L. & Bäckhed, F. Drug the bug! Cell 163, 1565–1566 (2015).
96. Luczynski, P. et al. Adult microbiota-deficient mice have distinct dendritic morphological changes: differential effects in the amygdala and hippocampus. Eur. J. Neurosci. (2016).
97. Ogbonnaya, E.S. et al. Adult hippocampal neurogenesis is regulated by the microbiome. Biol. Psychiatry 78, e7–e9 (2015).
98. Hoban, A.E. et al. Regulation of prefrontal cortex myelination by the microbiota. Transl. Psychiatry 6, e774 (2016).
99. Braniste, V. et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci. Transl. Med. 6, 263ra158 (2014).
100. Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18, 965–977 (2015).
101. Sudo, N. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. (Lond.) 558, 263–275 (2004).
102. Bercik, P. et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol. Motil. 23, 1132–1139 (2011).
103. Bravo, J.A. et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA 108, 16050–16055 (2011).
104. al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 141, 599–609.e3 (2011).
105. Clarke, G. et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol. Psychiatry 18, 666–673 (2013).
106. Hsiao, E.Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451–1463 (2013).
107. Niehus, R. & Lord, C. Early medical history of children with autism spectrum disorders. J. Dev. Behav. Pediatr. JDBP 27 (Suppl.), S120–S127 (2006).
108. Finegold, S.M. et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 16, 444–453 (2010).
109. Wang, L. et al. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig. Dis. Sci. 57, 2096–2102 (2012).
110. Mayer, E.A., Padua, D. & Tillisch, K. Altered brain-gut axis in autism: comorbidity or causative mechanisms? BioEssays 36, 933–939 (2014).
111. MacFabe, D.F. et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav. Brain Res. 176, 149–169 (2007).
112. Buffington, S.A. et al. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell 165, 1762–1775 (2016).
113. Sullivan, E.L., Nousen, E.K. & Chamlou, K.A. Maternal high fat diet consumption during the perinatal period programs offspring behavior. Physiol. Behav. 123, 236–242 (2014).
114. Connolly, N. et al. Maternal metabolic risk factors for autism spectrum disorder-An analysis of electronic medical records and linked birth data. Autism Res. 9, 829–837 (2016).
115. Benakis, C. et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat. Med. 22, 516–523; advance online publication (2016).
116. Niess, J.H. et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307, 254–258 (2005).
117. Houlden, A. et al. Brain injury induces specific changes in the caecal microbiota of mice via altered autonomic activity and mucoprotein production. Brain Behav. Immun. (2016).
118. Arrieta, M.-C., Stiemsma, L.T., Amenyogbe, N., Brown, E.M. & Finlay, B. The intestinal microbiome in early life: health and disease. Front Immunol. 5, 427 (2014).
119. Russell, S.L. et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep. 13, 440–447 (2012).
120. Arrieta, M.-C. et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 7, 307ra152 (2015).
121. Trompette, A. et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159–166 (2014).
122. Thorburn, A.N. et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat. Commun. 6, 7320 (2015).
123. Zeevi, D. et al. Personalized nutrition by prediction of Glycemic Responses. Cell 163, 1079–1094 (2015).
124. Vrieze, A. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–916.e7 (2012).
125. Hohmann, E.L., Ananthakrishnan, A.N. & Deshpande, V. Case records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N. Engl. J. Med. 371, 668–675 (2014).
126. Alang, N. & Kelly, C.R. Weight gain after fecal microbiota transplantation. Open Forum Infect. Dis. 2, ofv004 (2015).
127. Abrahamsson, T.R. et al. Low diversity of the gut microbiota in infants with atopic eczema. J. Allergy Clin. Immunol. 129, 434–440.e2 (2012).
128. Song, H., Yoo, Y., Hwang, J., Na, Y.-C. & Kim, H.S. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J. Allergy Clin. Immunol. 137, 852–860 (2016).
129. Hevia, A. et al. Intestinal dysbiosis associated with systemic lupus erythematosus. MBio 5, e01548–14 (2014).
130. Lepage, P. et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141, 227–236 (2011).
131. Takahashi, K. et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion 93, 59–65 (2016).
132. Kostic, A.D. et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe. 17, 260–273 (2015).
133. Alkanani, A.K. et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes 64, 3510–3520 (2015).
134. Chen, J. et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci. Rep. 6, 28484 (2016).
135. Tims, S. et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J. 7, 707–717 (2013).
136. Goodrich, J.K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).
137. Huurre, A. et al. Mode of delivery—effects on gut microbiota and humoral immunity. Neonatology 93, 236–240 (2008).
138. Dominguez-Bello, M.G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. USA 107, 11971–11975 (2010).
139. Bäckhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 17, 690–703 (2015).
140. Azad, M.B. et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG 123, 983–993 (2016).
141. Koleva, P.T., Kim, J.-S., Scott, J.A. & Kozyrskyj, A.L. Microbial programming of health and disease starts during fetal life. Birth Defects Res. C Embryo Today 105, 265–277 (2015).
142. Ley, R.E., Turnbaugh, P.J., Klein, S. & Gordon, J.I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
143. Duncan, S.H. et al. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl. Environ. Microbiol. 73, 1073–1078 (2007).
144. Dethlefsen, L., Huse, S., Sogin, M.L. & Relman, D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).
145. Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. Nature 500, 585–588 (2013).
146. David, L.A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
147. David, L.A. et al. Host lifestyle affects human microbiota on daily timescales. Genome Biol. 15, R89 (2014).
148. Hofstra, J.J. et al. Changes in microbiota during experimental human Rhinovirus infection. BMC Infect. Dis. 15, 336 (2015).
149. Dethlefsen, L. & Relman, D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. USA 108 (Suppl. 1), 4554–4561 (2011).